Metastatic Basal Cell Carcinoma: Next-Line Treatment After Smoothened Inhibitor Failure
Metastatic basal cell carcinoma (mBCC) is an advanced-stage disease that requires systemic management and close multidisciplinary oversight. When first-line systemic therapy does not achieve objective tumor response, a defined next-line strategy applies.
Previous Line — Why Escalation Is Needed
The recommended first approach for mBCC is multidisciplinary consultation together with systemic therapy using a smoothened (hedgehog pathway) inhibitor (oral vismodegib). The primary goal of this line is objective tumor shrinkage. When that goal is not reached — or when further treatment with a smoothened inhibitor is no longer feasible — the protocol escalates to the next line.
Next-Line Approach (Partial Overview)
Once smoothened inhibitor therapy is no longer viable, the management approach shifts to either a systemic cytotoxic option or a supportive and palliative framework — with the choice guided by individual patient factors.
Full criteria, sequencing, and structured evidence-based options are available in the complete protocol below.
References
DOI: 10.1016/j.jaad.2017.10.006
- Multidisciplinary consultation and smoothened inhibitors are recommended for patients with metastatic BCC.
- If treatment of metastatic BCC with smoothened inhibitors is not feasible, platinum-based chemotherapy or best supportive care is recommended.
- Patients with advanced disease should be provided with or referred for best supportive and palliative care, to optimize symptom management and maximize quality of life.
View source ↗